India ▾

Sun Pharmaceutical Industries Limited — Q4 FY26 earnings call

Call held 27 Apr 2026

Management summary

Sun Pharmaceutical Industries announced the acquisition of Organon & Company for an equity value of $3.99 billion and an enterprise value of $11.75 billion, aiming to transform Sun Pharma into a global pharma leader. The deal is expected to be EPS accretive from day one and generate $350 million in synergies over 2-4 years. While the acquisition brings significant debt, management plans to prioritize repayment and leverage Organon's global footprint and established brands for growth, particularly in women's health and biosimilars.

Highlights

  • Acquisition of Organon for an equity value of $3.99 billion and an enterprise value of $11.75 billion, expected to close in 6-9 months.

  • Combined company's revenues will be $12.4 billion, with the innovative part of the business moving from 20% to 27%.

  • Combined entities together generating free cash flows of close to $2 billion, $2.5 billion on an annual basis.

  • Significant potential synergies of about $350 million could be materialized in the next two to four years.

  • The transaction will be EPS accretive from the beginning (first 12 months of closure).

Concerns

  • Taking on a significant amount of debt, resulting in a net debt by EBITDA of 2.3x post-acquisition.

  • Organon's business has historically shown 'no growth', requiring Sun Pharma to find ways to grow it.

  • Dividend payments 'haven't fully reflected on this' post-acquisition, though continuing payment is considered.

Key financials

  1. Combined Revenue 12.4 Bn
  2. Organon EBITDA Margin 30%
  3. Combined Free Cash Flow 2 Bn
  4. Net Debt to EBITDA (Combined) 2.3×
  5. Organon Gross Debt 8.5 Bn
  6. Organon Cash 900 Mn
  7. Organon Net Debt Interest Charge 5.5%
  8. Synergies 350 Mn

What they filed

Q1 FY27: revenue up 2.6%, net profit up 49.7% against the same quarter last year.

₹ Cr · quarterly
Line itemQ2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26Q3 FY26Q4 FY26Q1 FY27
Revenue5,122 6,181 7,179 5,595 4,548 −11%5,688 −8%4,924 −31%5,741 +3%
EBITDA1,332 1,705 3,059 1,910 1,184 −11%1,759 +3%1,329 −57%1,964 +3%
Net profit838 1,156 2,042 745 564 −33%705 −39%609 −70%1,115 +50%
How to read this

₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.

Capital allocation

high confidence
  • Debt Gross $8.5 Bn · Net $7.6 Bn · 2.3× EBITDA Cost 5.5%
    • Refinance Intent to work with lenders for swap of some long-term bonds and financing through own bankers to achieve better cost of financing.
    However, if we look at the debt in context of the multiples of combined company EBITDA, then I think it's around 2.3 times, not very large by current standards of debt in other companies. However, we will remain focused on finding a way to paying down the debt as early as possible.
  • M&A Organon & Company Acquisition · Signed · Consideration ₹[object Object] (cash)

    Accelerating Sun's transformation toward becoming a global pharma company, strengthening innovative product business, achieving global reach, and becoming a partner of choice.

    EPS accretive from the beginning (first 12 months post-closure).

    Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, enclosed herewith a copy of the acquisition of Organon business by Sun Pharma investor conference call... In terms of the transaction overview, this transaction will get closed at $14 per share which represents an equity value of $3.99 billion and an enterprise value of $11.75 billion. The financing is going to be partly out of our own cash surplus which could be in the range of $2 billion to $2.5 billion and the balance would be funded through the committed financing from our banks... So this time we decided to do a cash deal... So we believe this will be EPS accretive from the beginning.
  • Liquidity Cash $3.1 Bn Sun Pharma has a strong balance sheet with $3.1 billion in cash, with $2 billion to $2.5 billion of this cash surplus being used for the acquisition financing.
    And most importantly, we have strong balance sheet with $3.1 billion, as a cash... The financing is going to be partly out of our own cash surplus which could be in the range of $2 billion to $2.5 billion and the balance would be funded through the committed financing from our banks.

Guidance & targets

Synergies

  • Synergy realization Synergies · next two to four years · High confidence $350 million
    There are also significant potential synergies that could come out, which we have highlighted could be in the range of about $350 million which could be materialized in the next two to four years.

    — Jayashree Satagopan

Profitability

  • EPS accretion Profitability · first 12 months of closure · High confidence Accretive
    So we believe this will be EPS accretive from the beginning.

    — Jayashree Satagopan

Debt

  • Debt repayment Debt · ongoing · High confidence As early as possible
    However, we will remain focused on finding a way to paying down the debt as early as possible.

    — Dilip Shanghvi

Growth

  • Organon established product business growth Growth · future · Medium confidence Single digit growth
    I'm hopeful that the established product business which is stagnant today and not growing will also turn around and will start showing some single digit growth, yes.

    — Kirti Ganorkar

  • Biosimilar segment growth Growth · next two to three years · Medium confidence Higher than 13%
    So we will also in-license biosimilar products so that the entire business of biosimilar which is today growing by 13% can even grow higher in next two to three years.

    — Kirti Ganorkar

Deal Closure

  • Acquisition closing timeline Deal Closure · from announcement · High confidence 6 to 9 months
    we expect this deal to close in about six to nine month time.

    — Jayashree Satagopan

What to watch in Q1 FY27

Debt repayment progress and net debt to EBITDA ratio

Next quarter and beyond
Current Net debt to EBITDA of 2.3x post-acquisition
Target Reduction in net debt and net debt to EBITDA

Why it matters

Debt reduction is a stated priority and crucial for financial health post-acquisition.

However, we will remain focused on finding a way to paying down the debt as early as possible.

Risks & concerns

  • Significant increase in debt post-acquisition

    high

    Sun Pharma will be taking on a significant amount of debt, leading to a net debt to EBITDA of 2.3x, with a focus on early repayment.

    Management acknowledged

  • Organon's historical 'no growth' and the challenge of revitalization

    medium

    Organon has shown no growth historically, presenting a challenge for Sun Pharma to find ways to grow the business.

    Management acknowledged

  • Potential impact on dividend payments due to increased debt

    medium

    The impact on dividend payments has not been fully reflected, though continuing payment is considered, and specific outcomes will be shared.

    Management acknowledged

  • Integration challenges (cultural fit, management bandwidth)

    medium

    Integration requires careful management of cultural fit and allocation of senior management bandwidth, though an integration management office will be formed.

    Analyst acknowledged

Q&A highlights

7 direct
Cultural fit and management bandwidth for integration Direct
I think like both Kirti and Jayashree explained in the presentation, we will be forming a integration management office which will both manage the integration as well as manage the transition. There will be a certain amount of time that of senior management which will be spent on this. However, what I'm excited about is the opportunity to be able to also strengthen the existing management capability of Sun because we will have a large number of performing managers coming in from Organon.

Addresses key operational risks of large acquisitions, particularly cultural integration and resource allocation, and highlights the potential for strengthening Sun Pharma's talent pool.

Asked by Kunal Dhamesha

Synergies breakdown and cost of debt Direct
As far as the synergies are concerned, as I mentioned the $350 million estimated is purely on the cost front where we think there are multiple opportunities that one could look at. We have opportunities in terms of procurement, there could be opportunities in terms of people working together, there could be opportunities also in terms of certain supply chain front... currently the debt profile of Organon, they have a gross debt of about $8.5 billion and cash of close to $900 million. The net debt is having an interest charge of about 5.5%.

Provides specifics on the nature of synergies (cost-driven) and details the inherited debt structure, which is a major financial component of the deal.

Asked by Kunal Dhamesha

Strategy for growing Organon's established brands Direct
So there are we have good number of ideas based on our previous experience in developing branded generic business is on a line extensions. So some of these products will go through clinical studies, some of these product can be approved based on bioequivalence studies, but some of these line extension would help us to grow this established product to the next level... I'm hopeful that the established product business which is stagnant today and not growing will also turn around and will start showing some single digit growth, yes.

Addresses how Sun Pharma plans to revitalize Organon's stagnant established brand portfolio, which is a key challenge and opportunity for the acquisition.

Asked by Vivek Agarwal

EPS accretion timeline and FTC divestments Direct
So we believe this will be EPS accretive from the beginning... You mean in the first 12 months of the closure of the transaction? Sorry if you could clarify. Yes, yes... there is a negligible overlap between Sun and Organon. It's a very negligible and the few product which we may have to divest, but other than that there is no major divestment required for the for the business going forward.

Clarifies the immediate financial impact (EPS accretion) and addresses potential regulatory hurdles or asset divestments, which are common concerns in large pharma M&A.

Asked by Shyam Srinivasan

Investment required to revive Organon's growth and impact on future M&A Partial
As I said, this would require in-licensing of product. And we will also look at in-licensing of product which are closer to market and it means that we will also need to invest in in-licensing of these products as we commercialize them... Now what do we do and when do we do next transaction, I don't think we can comment it right now.

Highlights the need for further investment in in-licensing to drive Organon's growth and indicates a cautious approach to further large M&A given the current debt.

Asked by Neha Manpuria

Change in acquisition blueprint (larger deals) and breaking into US commercial channel Direct
No, I think we've consistently maintained that we want to strengthen our capability to develop and strengthen our innovative product business. Organon gives us a what you call global reach both whenever we license or buy a company to launch the product in multiple geographies ourselves so that we can capture the full value... I think the idea is to strengthen our ability to become a partner of choice.

Explains the strategic shift towards larger acquisitions and how Organon fits into Sun Pharma's long-term goal of global reach and innovation.

Asked by Shashank Krishnakumar

Single biggest reason for bidding for Organon despite growth challenges Direct
No, I think if you look at numbers, it's very self-explanatory. Two different companies with similar top line and actually their EBITDA is higher than Sun, one valued at close to $10 billion, the other in excess of $40 billion. The key difference is the growth. What I think as a company we've demonstrated is our ability to find a way to grow the business.

Reveals the core investment thesis: acquiring a large, profitable, but stagnant asset at a relatively lower valuation with the belief that Sun Pharma can unlock growth.

Asked by Alankar Garude

Cross-selling opportunities for Sun's specialty products in Organon's markets Direct
I will use ILUMYA as an example, like you know now ILUMYA we have registered in more than 35 countries and still we are not present globally the way the Organon will have footprint across 140 countries, still an opportunity for ILUMYA to registered in large number of countries... So we can start the process of registering the product and post close transaction you can commercialize the product using the commercial vehicle what we have we will get through Organon.

Details a concrete plan for leveraging Organon's global commercial infrastructure to expand Sun Pharma's existing innovative product portfolio.

Asked by Kunal Dhamesha

2 min read 6 chapters

Detailed narrative

Acquisition Rationale and Strategic Fit

Sun Pharma announced the acquisition of Organon & Company, a move described as accelerating its transformation into a global pharma company. The deal aims to leverage Organon's strong brand equity, global commercial footprint across 140 countries, and leading position in women's health. Dilip Shanghvi noted that while Organon has historically shown no growth, Sun Pharma believes it can unlock significant value by growing the business. The combined entity will have revenues of $12.4 billion, with innovative medicines contributing 27% of sales.

Financial Impact and Synergies

The acquisition is valued at an equity value of $3.99 billion ($14 per share) and an enterprise value of $11.75 billion, expected to close in 6-9 months. Sun Pharma will fund the deal partly from its cash surplus ($2-2.5 billion) and committed bank financing. Post-acquisition, the combined entity's net debt to EBITDA is projected at 2.3x, with management prioritizing early debt repayment. The deal is expected to be EPS accretive from the beginning (first 12 months post-closure), with an estimated $350 million in cost synergies over 2-4 years from procurement, people, and supply chain optimization.

Organon's Business Profile

Organon is characterized by a stable EBITDA margin of 30% over the last five years and generates about $1 billion in free cash flow before financing. Its portfolio includes innovative medicines (33% of revenues) and established brands (55% of revenues), with 15 large brands exceeding $100 million in sales. Key therapeutic areas include women's health (contraception, fertility), where it holds leading positions, and biosimilars, with six products in its current portfolio. Organon also brings a legacy of developing complex products like Nexplanon and NuvaRing.

Growth Strategy for Combined Entity

Sun Pharma plans to drive growth by leveraging Organon's global platform for its innovative products like ILUMYA, VTAMA, and Emgality, expanding into new markets. For Organon's established brands, the strategy involves line extensions, clinical studies, and potentially combining products to achieve single-digit growth. The biosimilar segment, currently growing at 13%, will be expanded through in-licensing new products, utilizing Organon's existing portfolio (e.g., Renflexis, Hadlima) and commercial platform.

Geographic Expansion and Market Reach

The acquisition significantly expands Sun Pharma's global footprint, increasing its presence to over 150 markets, with 18 markets generating over $100 million in revenue. A key focus is China, where Organon has a substantial presence with over $800 million in sales and eight large brands, providing Sun Pharma a scale platform to launch its innovative products and pursue in-licensing opportunities. The combined entity will also strengthen its position in Europe and gain entry into new markets like South Korea.

Integration Approach and Learnings

Sun Pharma plans to establish an integration management office to manage the transition and integration process over 6-9 months. Drawing on past experiences with Taro and Ranbaxy acquisitions, the company emphasizes an open-minded approach to understanding Organon's strengths and weaknesses. Management believes the integration will strengthen Sun Pharma's existing capabilities by incorporating performing managers from Organon and enhancing its ability to attract future talent.

This is an AI-generated summary of a publicly available earnings call transcript.
View original transcript

More Healthcare earnings calls